Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of March 2021. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure and voting rights.
- Issued Share Capital (as of Feb 28, 2021): 5,386,282,143 Ordinary Shares of 25 pence each.
- Treasury Shares: 355,205,950 Ordinary Shares.
- Total Voting Rights: 5,031,076,193.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. The document is a static notification of share capital status as of February 28, 2021.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The primary purpose of this filing is to establish the denominator for shareholder notification calculations under FCA rules.
Key Facts for Investor Verification
- Verify the total number of voting rights (5,031,076,193) to determine if notification thresholds under FCA rules have been met.
- Confirm the number of shares held in Treasury (355,205,950) which are excluded from voting rights.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly earnings releases for financial metrics.